A006280 Stock Overview
Green Cross Corporation, a biopharmaceutical company, develops drugs and vaccines in South Korea.
Green Cross Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₩123,500.00|
|52 Week High||₩325,000.00|
|52 Week Low||₩121,000.00|
|1 Month Change||-20.58%|
|3 Month Change||-26.27%|
|1 Year Change||-61.88%|
|3 Year Change||8.81%|
|5 Year Change||-38.40%|
|Change since IPO||-58.50%|
Recent News & Updates
|A006280||KR Biotechs||KR Market|
Return vs Industry: A006280 underperformed the KR Biotechs industry which returned -48.4% over the past year.
Return vs Market: A006280 underperformed the KR Market which returned -29% over the past year.
|A006280 Average Weekly Movement||4.8%|
|Biotechs Industry Average Movement||7.4%|
|Market Average Movement||5.9%|
|10% most volatile stocks in KR Market||10.6%|
|10% least volatile stocks in KR Market||3.6%|
Stable Share Price: A006280 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: A006280's weekly volatility (5%) has been stable over the past year.
About the Company
Green Cross Corporation, a biopharmaceutical company, develops drugs and vaccines in South Korea. The company provides plasma derivatives, including albumin, immunoglobulin, and antithrombin; and vaccines for hepatitis-B, Hantavirus hemorrhagic fever, influenza, flu, and varicella. It also offers prescription drugs for the bleeding symptom control and hemostasis for persons with hemophilia A; prevention and treatment of bleeding episodes induced by hemophilia A and post-operative treatment; and treatment of neutropenia, hunter syndrome, and liver cancer, as well as treatment of anti-inflammation, pain relief, and osteoarthritis.
Green Cross Fundamentals Summary
|A006280 fundamental statistics|
Is A006280 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A006280 income statement (TTM)|
|Cost of Revenue||₩1.11t|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||10.93k|
|Net Profit Margin||7.30%|
How did A006280 perform over the long term?See historical performance and comparison
1.6%Current Dividend Yield
Is A006280 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 6/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A006280?
Other financial metrics that can be useful for relative valuation.
|What is A006280's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does A006280's PE Ratio compare to its peers?
|A006280 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
A005250 Green Cross Holdings
A290650 L&C Bio
A006280 Green Cross
Price-To-Earnings vs Peers: A006280 is good value based on its Price-To-Earnings Ratio (11.3x) compared to the peer average (27.5x).
Price to Earnings Ratio vs Industry
How does A006280's PE Ratio compare vs other companies in the KR Biotechs Industry?
Price-To-Earnings vs Industry: A006280 is good value based on its Price-To-Earnings Ratio (11.3x) compared to the KR Biotechs industry average (20.1x)
Price to Earnings Ratio vs Fair Ratio
What is A006280's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||11.3x|
|Fair PE Ratio||21.8x|
Price-To-Earnings vs Fair Ratio: A006280 is good value based on its Price-To-Earnings Ratio (11.3x) compared to the estimated Fair Price-To-Earnings Ratio (21.8x).
Share Price vs Fair Value
What is the Fair Price of A006280 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A006280 (₩123500) is trading below our estimate of fair value (₩184334.22)
Significantly Below Fair Value: A006280 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Green Cross forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A006280's forecast earnings growth (9.5% per year) is above the savings rate (3.6%).
Earnings vs Market: A006280's earnings (9.5% per year) are forecast to grow slower than the KR market (17% per year).
High Growth Earnings: A006280's earnings are forecast to grow, but not significantly.
Revenue vs Market: A006280's revenue (3.7% per year) is forecast to grow slower than the KR market (9.6% per year).
High Growth Revenue: A006280's revenue (3.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A006280's Return on Equity is forecast to be low in 3 years time (5.9%).
Discover growth companies
How has Green Cross performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A006280 has a large one-off gain of ₩70.1B impacting its June 30 2022 financial results.
Growing Profit Margin: A006280's current net profit margins (7.3%) are higher than last year (6.2%).
Past Earnings Growth Analysis
Earnings Trend: A006280's earnings have grown significantly by 21.8% per year over the past 5 years.
Accelerating Growth: A006280's earnings growth over the past year (33.4%) exceeds its 5-year average (21.8% per year).
Earnings vs Industry: A006280 earnings growth over the past year (33.4%) underperformed the Biotechs industry 33.4%.
Return on Equity
High ROE: A006280's Return on Equity (9.3%) is considered low.
Discover strong past performing companies
How is Green Cross's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: A006280's short term assets (₩1,105.9B) exceed its short term liabilities (₩567.0B).
Long Term Liabilities: A006280's short term assets (₩1,105.9B) exceed its long term liabilities (₩424.0B).
Debt to Equity History and Analysis
Debt Level: A006280's net debt to equity ratio (22.4%) is considered satisfactory.
Reducing Debt: A006280's debt to equity ratio has increased from 28.9% to 35.9% over the past 5 years.
Debt Coverage: A006280's debt is well covered by operating cash flow (22%).
Interest Coverage: A006280's interest payments on its debt are well covered by EBIT (8.9x coverage).
Discover healthy companies
What is Green Cross's current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|Green Cross Dividend Yield vs Market|
|Company (Green Cross)||1.6%|
|Market Bottom 25% (KR)||1.1%|
|Market Top 25% (KR)||3.6%|
|Industry Average (Biotechs)||0.7%|
|Analyst forecast in 3 Years (Green Cross)||1.6%|
Notable Dividend: A006280's dividend (1.62%) is higher than the bottom 25% of dividend payers in the KR market (1.14%).
High Dividend: A006280's dividend (1.62%) is low compared to the top 25% of dividend payers in the KR market (3.57%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, A006280 has been paying a dividend for less than 10 years.
Growing Dividend: A006280's dividend payments have increased, but the company has only paid a dividend for 6 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (18.3%), A006280's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (135.3%), A006280's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Il-Sup Huh (68 yo)
Mr. Il-Sup Huh, Ph.D. has been the Chairperson of GC Pharma (formerly, Green Cross Corporation) since 2009 and serves as its Chief Executive Officer. Mr. Huh serves as Chairperson and Chief Executive Offic...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
|Employee Share Scheme||4,460||0.04%|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Green Cross Corporation's employee growth, exchange listings and data sources
- Name: Green Cross Corporation
- Ticker: A006280
- Exchange: KOSE
- Founded: 1967
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₩1.410t
- Shares outstanding: 11.41m
- Website: https://www.globalgreencross.com
Number of Employees
- Green Cross Corporation
- 107, Ihyeon-ro 30beon-gil
- South Korea
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|A006280||KOSE (Korea Stock Exchange)||Yes||Common Stock||KR||KRW||Dec 1993|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/03 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.